Media Room Menu
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Jun 12, 2016- Both pivotal studies demonstrated superior reduction in HbA1c versus insulin glargine and versus lixisenatide -
-
Jun 6, 2016- These data, along with previous Phase 3 studies, will be part of a U.S. regulatory submission for dupilumab, which is on track for Q3 of 2016 -
-
May 25, 2016- FDA decisions on the investigational fixed-ratio combination of basal insulin glargine 100 Units/mL and GLP-1 receptor agonist lixisenatide and investigational lixisenatide anticipated in Q3 2016 -
-
Apr 27, 2016- Collaborations Will Work towards Predicting Medication Adherence -
-
Apr 1, 2016- Dupilumab is first systemic therapy to show positive Phase 3 results in patients with moderate-to-severe atopic dermatitis, a serious, chronic inflammatory skin disease marked by widespread rash, itching and associated psychosocial comorbidities -
-
Mar 29, 2016Pre-clinical immunogenicity and efficacy data published in Journal of Virology
-
Mar 4, 2016Praluent is now covered by most health insurance and Medicare plans
-
Feb 22, 2016- FDA decision anticipated in August 2016 -
-
Feb 12, 2016America's Leading National Consumer Research Survey Ranks ACT Advanced Care #1 in "Oral Care" Category
-
Feb 2, 2016Study Evaluated Adult Patients with Chronic Sinusitis with Nasal Polyposis who did not Respond to Intranasal Corticosteroids
-
Feb 2, 2016Six researchers each receive $1.625 million in "Pathway to Stop Diabetes®" awards
-
Jan 28, 2016- Aims to advance animal health though internet-connected technology and networks -
-
Dec 18, 2015Record-breaking holiday gift drive responds to increased homelessness rates
-
Dec 11, 2015Praluent® is the only PCSK9 inhibitor preferred across UnitedHealth Group formularies, including OptumRx and UnitedHealthcare Commercial, Medicare, and Managed Medicaid formularies